Insider Selling: Paratek Pharmaceuticals Inc (PRTK) CFO Sells $24,944.64 in Stock
Paratek Pharmaceuticals Inc (NASDAQ:PRTK) CFO Douglas W. Pagan sold 2,784 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $8.96, for a total value of $24,944.64. Following the sale, the chief financial officer now directly owns 126,004 shares of the company’s stock, valued at $1,128,995.84. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
PRTK opened at $9.38 on Friday. Paratek Pharmaceuticals Inc has a 52 week low of $8.69 and a 52 week high of $23.50. The company has a debt-to-equity ratio of 2.37, a quick ratio of 7.88 and a current ratio of 7.88.
Paratek Pharmaceuticals (NASDAQ:PRTK) last released its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.02). The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.10 million. Paratek Pharmaceuticals had a negative return on equity of 106.39% and a negative net margin of 1,961.41%. Sell-side analysts expect that Paratek Pharmaceuticals Inc will post -3.37 earnings per share for the current year.
A number of equities research analysts recently issued reports on the company. BidaskClub raised Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 6th. Guggenheim set a $26.00 price objective on Paratek Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, October 3rd. Zacks Investment Research upgraded Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 19th. ValuEngine upgraded Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 2nd. Finally, Cantor Fitzgerald restated a “buy” rating and set a $50.00 price objective on shares of Paratek Pharmaceuticals in a report on Thursday, August 2nd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. Paratek Pharmaceuticals has an average rating of “Buy” and an average target price of $31.50.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Further Reading: How accurate is the Rule of 72?
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.